Antidepressant and antipsychotic drug prescribing in Lombardy;La prescrizione di antidepressivi e antipsicotici nella popolazione generale in Lombardia

Epidemiologia e Psichiatria Sociale

Volumn 15, Issue 1, 2006, Pages 59-70

  Percudani, Mauro ^a,c   Barbui, Corrado ^b   Portino, Ida ^a   Tansella, Michele ^b   Petrovich, Lorenzo ^a  

^a Unità Organizzativa Governo della prevenzione e tutela sanitaria   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Direzione Generale Sanita   (Italy)

Author keywords

Antidepressants; Antipsychotics; Cerebrovascular events; Epidemiology; Prevalence

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; AGING; ARTICLE; CEREBROVASCULAR ACCIDENT; DATA BASE; DRUG EXPOSURE; DRUG USE; DRUG UTILIZATION; HUMAN; ITALY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE;

EID: 33645401876     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1121189x00002049     Document Type: Article

References (38)

1. Andretta M., Font M., Pinato S. & Mezzalira L. (2003). Antidepressivi: confronta tra conoscenza e pratica. XXIV Congresso Nazionale SIFO. Percorsi diagnostico-terapeutici in sanità: obiettivi e responsabilità del farmacista pubblico. Giornale Italiano di Farmacia Clinica 17, 30.
2. Barbui C., Broglio E. & Costa Laia A. (2003). Cross-sectional database analysis of antidepressant prescribing in Italy. Journal of Clinical Psychopharmacology 23, 31-34.
3. Barbui C., Percudani M., Fortino I., Tansella M. & Petrovich L. (2005). Past use of selective serotonin reuptake inhibitors and the risk of cerebrovascular events in the elderly. International Clinical Psychopharmacology 20(3), 169-171.
4. Bland R.C., Orn H. & Newman S.C. (1988). Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatrica Scandinavica, Supplementum 338, 24-32.
5. Blazer D.G., Kessler R.C. & McGonagle K.A. (1994). The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. American Journal of Psychiatry 151, 979-986.
6. CERGAS (2005). Rapporta Osservatorio Farmaci (OSFAR), Retrieved November 10, 2005, from http://www.cergas.info/researchID. cfm?id=1041
7. Clavenna A., Bonati M., Rossi E. & De Rosa, M. (2004). Increase in non evidence based use of antidepressants in children is cause for concern. British Medical Journal 328, 711-712.
8. Dewa C.S., Remington G., Herrmann N., Fearnley J. & Goering P. (2002). How much are atypical antipsychotic agents being used, and do they reach the population who need them? A Canadian experience. Clinical Therapeutics 24, 1466-1476.
9. Dubini A., Mannheimer R. & Pancheri P. (2001). Depression in the community: results of the first Italian survey. International Clinical Psychopharmacology 16, 49-53.
10. EMEA (2005). EMEA public statement on the safety of olanzapine. Retrieved November 10, 2005, from http://www.emea.eu.int/ pdfs/human/press/pus/085604en. pdf
11. ESEMeD/MHEDEA 2000 Investigators (2004). Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica, Supplementum. 420, 21-27.
12. Hamann J., Ruppert A., Auby P., Pugner K. & Kissling W. (2003). Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. International Clinical Psychopharmacology 18, 237-242.
13. Hemels M.E.H., Koren G. & Einarson T.R. (2002). Increased use of antidepressants in Canada: 1981-2000. Annals of Pharmacotherapy 36, 1375-1379.
14. Herrmann N., Mamdani M. & Lanctot K.L. (2004). Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry 161, 1113-1115.
15. Jureidini J.M., Doecke C.J. & Mansfield P.R. (2004). Efficacy and safety of antidepressants for children and adolescents. British Medical Journal 328, 879-883.
16. Kessler R.C., McGonagle K.A. & Zhao S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 51, 8-19.
17. Knottnerus A. & Dinant G.J. (1997). Medicine based evidence, a pre-requisite for evidence based medicine. British Medical Journal 315, 1109-1110.
18. Lawrenson R.A., Tyrer F. & Newson R.B. (2000). The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. Journal of Affective Disorders 59, 149-157.
19. Mann A.H., Schneider J. & Mozley C.G. (2000). Depression and the response of residential homes to physical health needs. International Journal of Geriatric Psychiatry 15, 1105-1112.
20. McConville B.J. & Sorter, M.T. (2004). Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. Journal of Clinical Psychiatry 65, Suppl. 6, 20-29.
21. Meijer W.E., Heerdink E.R., Nolen W.A., Herings R.M., Leufkens H.G. & Egberts A.C. (2004). Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Archives of Internal Medicine 164, 2367-2370.
22. Mond J., Morice R., Owen C. & Korten A. (2003). Use of antipsychotic medications in Australia between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry 37, 55-61.
23. Olfson M., Shea S., Feder A., Fuentes M., Nomura Y., Gameroff M. & Weissman M.M. (2000). Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Archives of Family Medicine 9, 876-883.
24. Pariante C.M. & Tansella M. (2005). Controversises in antidepressant therapy. Epidemiologia e Psichiatria Sociale 14 (2), 51-54.
25. Percudani M., Barbui C., Fortino I. & Petrovich L. (2004a). Antidepressant drug use in Lorabardy, Italy: a population based study. Journal of Affective Disorders 83, 169-175.
26. Percudani M., Barbui C., Fortino I. & Petrovich L. (2004b). Antipsychotic drug prescribing in the elderly is cause for concern. International Clinical Psychopharmacology 19, 347-350.
27. Percudani M., Barbui C., Fortino I. & Petrovich L. (2005a). Epidemiology of first- and second-generation antipsychotic agents in Lombardy, Italy. Pharmacopsychiatry 38, 128-131.
28. Percudani M., Barbui C., Fortino I. & Petrovich L. (2005b). Worrying patterns of out-patient psychotropic drug prescribing in children and adolescents. Psychotherapy and Psychosomatic 74, 189-190.
29. Percudani M., Barbui C., Fortino I. & Petrovich L. (2005c). Antidepressant drug prescribing among elderly subjects: a population-based study. International Journal of Geriatric Psychiatry 20, 113-118.
30. Percudani M., Barbui C., Fortino I., Tansella M. & Petrovich L. (in press). Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. Journal of Clinical Psychopharmacology
31. Pietraru C., Barbui C., Poggio L. & Tognoni G. (2001). Antidepressant drug prescribing in Italy, 2000: analysis of a general practice database. European Journal of Clinical Pharmacology 57, 605-609.
32. Rosholm J.U., Andersen M. & Gram L.F. (2001). Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. European Journal of Clinical Pharmacology 56, 923-929.
33. Rothbard A.B., Kuno E. & Foley K. (2003). Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophrenia Bulletin 29, 531-540.
34. Santamaria B., Perez M., Montera D., Madurga M. & de Abajo F.J. (2002). Use of antipsychotic agents in Spain through 1985-2000. European Psychiatry 17, 471-476.
35. Scillia C.V., Maione M.R, Piro B., Ferraiolo R., Talarico A., De Stefano G., Sacco F., Servadei F., Garaffo C., Di Lorenzo R. & De Marco G. (2003). Studio retrospettivo multicentrico sull'utilizzo degli antipsicotici classici verso quelli atipici in quattro AA.SS.LL. della Calabria. XXIV Congresso Nazionale SIFO. Percorsi diagnostico-terapeutici in sanità: obiettivi e responsabilità del farmacista pubblico. Giomale Italiano di Farmacia Clinica 17, 30-31.
36. Smith D.A. & Beier M.T. (2004). Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypothesis for an underlying mechanism. Journal of the American Medical Association 5, 129-132.
37. Whittington C.J., Kendall T., Fonagy P., Cottrell D., Cotgrove A. & Boddington E. (2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancer 363, 1341-1345.
38. Zimmerman M., Mattia J.I. & Posternack M.A. (2002). Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? American Journal of Psychiatry 159, 469-473.